224 related articles for article (PubMed ID: 23663707)
1. [Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma].
Voilliot-Trotot C; Granel-Brocard F; Geoffrois L; Tréchot P; Nguyen-Thi P; Schmutz JL; Barbaud A
Ann Dermatol Venereol; 2013 May; 140(5):353-62. PubMed ID: 23663707
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
[TBL] [Abstract][Full Text] [Related]
3. Onychopathy induced by temsirolimus, a mammalian target of rapamycin inhibitor.
Peuvrel L; Quéreux G; Brocard A; Saint-Jean M; Dréno B
Dermatology; 2012; 224(3):204-8. PubMed ID: 22614575
[TBL] [Abstract][Full Text] [Related]
4. Management of mTOR inhibitor side effects.
Creel PA
Clin J Oncol Nurs; 2009 Dec; 13 Suppl():19-23. PubMed ID: 19948456
[TBL] [Abstract][Full Text] [Related]
5. [mTOR inhibitors].
Oya M
Nihon Rinsho; 2010 Jun; 68(6):1067-71. PubMed ID: 20535957
[TBL] [Abstract][Full Text] [Related]
6. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
7. [Use of mTOR-inhibitors in solid tumors].
Seidel C; Grünwald V
Med Monatsschr Pharm; 2011 Apr; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
9. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
10. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
11. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
12. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
[TBL] [Abstract][Full Text] [Related]
13. Angioedema in a patient with renal cell cancer treated with everolimus in combination with an angiotensin-converting enzyme inhibitor.
Rothermundt C; Gillessen S
J Clin Oncol; 2013 Feb; 31(5):e57-8. PubMed ID: 23295800
[No Abstract] [Full Text] [Related]
14. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.
Armstrong AJ; George DJ; Halabi S
J Clin Oncol; 2012 Sep; 30(27):3402-7. PubMed ID: 22891270
[TBL] [Abstract][Full Text] [Related]
15. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
Büchler T; Dusek L; Fínek J; Poprach A; Budnáková D; Kandrnal V; Jarkovský J; Bortlícek Z; Klimes D; Abrahámová J; Vyzula R
Klin Onkol; 2011; 24(5):389-92. PubMed ID: 22070021
[TBL] [Abstract][Full Text] [Related]
16. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
17. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
Grgic T; Mis L; Hammond JM
Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
[TBL] [Abstract][Full Text] [Related]
18. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
19. Eosinophilic rash secondary to temsirolimus.
Gandhi M; Kuzel T; Lacouture M
Clin Genitourin Cancer; 2009 Aug; 7(2):E34-6. PubMed ID: 19692320
[TBL] [Abstract][Full Text] [Related]
20. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors.
Sibaud V; Dalenc F; Mourey L; Chevreau C
Acta Derm Venereol; 2011 Sep; 91(5):584-5. PubMed ID: 21667012
[No Abstract] [Full Text] [Related]
[Next] [New Search]